BIOMAT Database Logo BIOMAT Database Logo

Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study. 2012

J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Service de Médecine Interne et Vasculaire B, CHRU de Tours, France, Tours, France. magnant@med.univ-tours.fr

Hypothesizing a pathophysiological role of anti-topoisomerase I antibodies (anti-topo I) through autoantibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic effectors expressing receptors for the Fc portion of IgG in systemic sclerosis (SSc), 267 SSc patients (56 with anti-topo I and 102 with anti-centromere antibodies (ACA)) were genotyped for the functional FCGR3A-V158F polymorphism. A descriptive analysis of patients according to their clinical and immunological status and FCGR3A-158 V/F genotypes was performed using multiple correspondence analysis. This descriptive analysis revealed an association between the FCGR3A-158 VV genotype and the presence of anti-topo I. By contrast, no relationship was found between FCGR3A polymorphism and the presence of ACA. SSc patients with anti-topo I appear to be more frequently homozygous for the high-affinity FcγRIIIA-coding allele, suggesting that some autoantibodies may be pathogenic through ADCC.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D002503 Centromere The clear constricted portion of the chromosome at which the chromatids are joined and by which the chromosome is attached to the spindle during cell division. Centromeres
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody

Related Publications

J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.
November 2020, Arthritis & rheumatology (Hoboken, N.J.),
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
March 2016, International journal of rheumatic diseases,
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
December 2006, Arthritis and rheumatism,
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Anti-topoisomerase I autoantibodies in systemic sclerosis.
July 2009, Autoimmunity reviews,
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis.
December 2009, The Journal of rheumatology,
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Serum levels of anti-Fcγ receptor IIB/C antibodies are increased in patients with systemic sclerosis.
November 2014, The Journal of dermatology,
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.
November 2022, Rheumatology (Oxford, England),
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Expansion of Fcγ Receptor IIIa-Positive Macrophages, Ficolin 1-Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis.
February 2022, Arthritis & rheumatology (Hoboken, N.J.),
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase I Antibody-Positive Systemic Sclerosis.
September 2017, The Journal of investigative dermatology,
J Magnant, and M Ohresser, and Y Allanore, and M de Monte, and M Lafosse-Marin, and D Degenne, and J L Guilmot, and H Watier, and E Diot
Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma).
July 1996, Israel journal of medical sciences,
Copied contents to your clipboard!